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Abstract
Exacerbations of chronic obstructive pulmonary disease (COPD) have a negative effect on the clinical course and outcome of the 
disease thus causing considerable social and economic burden. As the natural course of the disease may vary, the treatment 
should take into account an individual approach to a patient. The appropriate treatment makes it possible to control the symptoms, 
improves effort tolerance and decreases the risk of exacerbations and death. Tiotropium is a muscarinic receptor antagonist, 
which is taken once daily, in maintenance therapy, in every stage of the disease progress. The efficacy of tiotropium in regards 
to exacerbations of chronic obstructive pulmonary disease has been evaluated in many clinical trials against placebo and several 
different active comparators. This review presents the results of those studies with the main goal to evaluate the efficacy of 
treatment with tiotropium in terms of prevention and course of exacerbations.
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Streszczenie
Zaostrzenia przewlekłej obturacyjnej choroby płuc (POChP) mają istotny wpływ na przebieg kliniczny oraz stopień kontroli astmy, 
stanowiąc istotne obciążenie społeczne i ekonomiczne. Historia naturalna i przebieg choroby mogą się różnić między pacjentami, 
dlatego leczenie powinno uwzględniać indywidualizację terapii. Odpowiednie leczenie pozwala na kontrolowanie objawów, popra-
wia tolerancję wysiłku i zmniejsza ryzyko zaostrzeń i śmierci. Tiotropium jest antagonistą receptora muskarynowego, podawanym 
raz na dobę, w terapii podtrzymującej na praktycznie każdym etapie rozwoju choroby. Skuteczność tiotropium w odniesieniu do 
zaostrzenia przewlekłej obturacyjnej choroby płuc oceniano w wielu badaniach klinicznych w porównaniu z placebo i  innymi 
lekami. W pracy przedstawiono wyniki tych badań, ze szczególnym uwzględnieniem oceny skuteczności tiotropium w zakresie 
zapobiegania zaostrzeniom.
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Epidemiology
Chronic Obstructive Pulmonary Disease 
(COPD) is one of the major global causes of mor-
bidity and mortality. The disease causes over 
3 million deaths globally, which accounts for 
6% of all deaths [1]. Approximately 5−10% of 
adult population aged above 40 years in Europe 
is suffering from COPD. Mortality caused by 
COPD in the population of Europe is estimated at 
18/100,000 people (age-standardised coefficient) 
[2]. The results of a multi-center, international 
epidemiological study, called BOLD (Burden of 
Obstructive Lung Disease), which assessed in-
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cidence and factors of the diseases progress, have 
shown the incidence to vary from one country to 
another and to be higher in males than in females [3]. 
The incidence of COPD has been found to incre-
ase with age and the number of cigarettes smoked 
(the number of pack-years) [4, 5]. The incidence 
of COPD in the southern region of Poland (Ma-
łopolska), as estimated in the study, was 10.9% 
(13.3% of males and 8.6% of females) [6].
COPD is a disease with multifactorial aetiolo-
gy and varied course, and it requires an individual 
approach to each patient. A secondary analysis of 
the findings of the ECLIPSE study (Evaluation of 
COPD Longitudinally to Identify Predictive Surro-
gate Endpoints) conducted with currently applied 
categorisation of patients into groups A, B, C, D 
(as per 2011 GOLD guidelines), revealed signifi-
cant differences between groups of patients across 
a wide range of the parameters under analysis [7]. 
It was observed that patients who were initially 
classified into groups A or D usually remained in 
those groups after 3 years of observation, unlike 
the patients initially assigned to groups B or C. 
The risk of exacerbations was found to increase 
with the disease category from A to D, whereas 
the risk of hospitalisation and mortality was 
the lowest in group A, and the highest in group 
D, with medium and equal levels in groups B 
and C, although group B by definition includes 
patients with mild or moderate obstruction and 
a lower risk of exacerbations. Moreover, the hi-
ghest percentage of patients with co-morbidities 
and patients with chronic systemic inflammation 
was found in group B. These observations can 
have important clinical implications as they sug-
gest that patients classified into group B should be 
examined particularly actively for co-morbidities 
because there may be other causes of hospitalisa-
tion and mortality in this group of patients other, 
than only severe exacerbations of COPD. 
The choice of therapy depends on the catego-
ry into which a patient has been classified (A, B, C 
or D according to the latest GOLD guidelines) [8]. 
The appropriately selected treatment makes it 
possible to control the symptoms, improves effort 
tolerance and decreases the risk of exacerbations 
and death. 
Exacerbations of COPD
According to GOLD, “an exacerbation of 
COPD is defined as an acute event characterized 
by a worsening of the patient’s respiratory symp-
toms that is beyond normal day-to-day variations 
and leads to a change in medication” [8]. 
Exacerbations of COPD are characterised by 
sudden increase in breathlessness, cough and/or 
increase in the volume of sputum. Severe exa-
cerbations involve worsening of gas exchange, 
hypoxemia, which may be accompanied by hy-
percapnia. It is estimated that as many as 50% of 
all exacerbations are not reported by patients and 
remain untreated. Although their course may be 
mild, unreported exacerbations are not without 
an effect on the health status [9, 10]. Exacerba-
tions accelerate the loss of pulmonary function, 
which is typical of COPD and which results in 
worse effort tolerance and a decrease in patients’ 
daily activity. Episodes of severe exacerbations le-
ading to hospitalizations are found in all patients, 
regardless of the disease stage and they have 
a negative impact on prognosis – as they contribu-
te to increased mortality. Patients at high risk of 
exacerbations leading to hospitalisation are those 
with a history of similar events as well as patients 
with worsened pulmonary function, deteriorated 
health status, leukocytosis or symptoms of pul-
monary oedema revealed radiographically [11]. 
Frequent exacerbations entail large economic 
and social costs which are generated by more 
frequent outpatient visits, hospitalisations, in-
creased consumption of drugs, sick leaves and 
disability benefits [8, 12]. Prevention, active and 
early diagnosis and early, correct treatment of 
exacerbations is of key importance in efforts to 
reduce the costs associated with COPD. 
The observations made as part of the ECLIPSE 
study showed that the frequency of exacerbations 
increases with the disease progression, although 
a group of particularly susceptible patients can 
be identified, defined as those who suffer from 
exacerbation episodes relatively often (at least 
twice a year) [13]. This attracted attention to 
the existence of a phenotype which involves 
frequent exacerbations, regardless of the degree 
of airway obstruction. The phenotype with frequ-
ent exacerbations was stable during a three-year 
observation (Table 1).
Causes of exacerbations 
Impairment of the topical defensive mecha-
nisms within the respiratory system makes pa-
tients with COPD more susceptible to infections. 
Viral infections of upper airways are the cause 
of 30−60% of all the exacerbations [15]. Usual-
ly, viral agents include rhinoviruses (20–25%), 
whereas RSV, influenza viruses, para-influenza 
viruses, adenoviruses and coronaviruses cause 
5−10% of all COPD exacerbations. Bacteria 
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Table 1.  Characteristics of the phenotype of COPD with 
frequent exacerbations according to [14]
Tabela 1.  Charakterystyka fenotypu pacjentów z POChP  
i częstymi zaostrzeniami choroby [14]
Faster deterioration in FEV1
Increased risk of hospitalisation and mortality
Exacerbated inflammatory condition (higher concentration  
of IL-6, fibrinogen, CRP)
Higher susceptibility to viral infections
A larger number of bacteria that colonise lower respiratory tract
Lower quality of life (as measured by SGRQ*)
An increased risk of cardiovascular diseases
*St George’s Respiratory Questionnaire 
cause 50% of all the exacerbations. Majority of 
exacerbations are caused by: Haemophilus in-
fluenzae (20−30%) Streptococcus pneumoniae 
(10−15%) and Moraxella catarrhalis (10–15%). 
Bacterial aetiology of exacerbations may vary and 
depend on the disease advancement, frequency of 
exacerbations and the type of antibiotic therapy 
applied. Pseudomonas aeruginosa are frequently 
isolated in patients with severe exacerbations, in 
an advanced stage of the disease (5−10%). There 
has been a low correlation shown to exist between 
acquisition of a new strain of H. influenzae, 
S. pneumoniae and M. catarrhalis and exacerba-
tion of COPD [15]. Compared to exacerbations 
of COPD with bacterial aetiology, exacerbations 
initiated by viruses and exacerbations with mixed 
(viral and bacterial) aetiology have a more severe 
course, they last longer and the risk of hospitali-
sation is higher [9]. 15−20% of exacerbations are 
caused by non-infection-related factors, including 
air pollution and tobacco smoking. Exacerbation 
may also result from incorrect drug inhalation or 
from giving up maintenance therapy. 
Prevention of exacerbations
All measures which lead to a decrease in the 
incidence of exacerbations are beneficial both 
from the perspective of a patient as they contri-
bute to the improvement of the quality of life and 
slowing down the disease progression, and from 
the perspective of the healthcare system as they 
reduce the cost of COPD treatment. The recom-
mended measures include giving up smoking, 
vaccinations against influenza and pneumococci 
(especially in patients aged > 65 years), respira-
tory rehabilitation and daily exercise [8]. 
Chronic use of antibiotics is not recommen-
ded in the prevention of COPD exacerbations 
due to insufficient clinical evidence to confirm 
the efficacy and safety of such measure [8]. 
Some analyses have suggested benefits to be 
gained from using antibiotics in COPD patients, 
especially at an advanced stage of the disease. 
A meta-analysis of 6 clinical trials conducted with 
1677 patients with severe and very severe COPD, 
most of them with a history of at least one episode 
of exacerbation, has revealed the risk of exacer-
bations in patients who receive macrolides being 
lower by 37.3% than in patients who received 
placebo [16]. The risk of hospitalisation has also 
been shown to be lower by 21% in patients who 
received an antibiotic. On the other hand some 
issues of potential safety of chronic antibiotic use 
and risk of increase of antibiotic resistance at the 
population level are raised. Further studies are 
needed to clarify the potential role of antibiotics 
in the prevention of COPD exacerbations. 
The role of tiotropium in therapy of chronic 
obstructive pulmonary disease — a review  
of clinical trials
Tiotropium bromide is a long acting and rel-
atively selective muscarinic antagonist (LAMA). 
It is the slowest to dissociate from the M3 recep-
tor, which results in its considerable and pro-
longed bronchodilating effect. Bronchodilation 
is a result of local, rather than systemic, effect. 
The onset of the drug action takes place after 
approx. 30 minutes and its action is maintained 
for over 24 hours. 
Tiotropium is used in maintenance therapy 
in every category of COPD advancement; it is 
a second choice therapy in category A. Tiotropi-
um can be taken once daily at the dose of 18 μg 
from a dry powder inhaler (Hendihaler) or at the 
dose of 5 μg (two actuation 2.5 μg each) from 
a soft mist inhaler (Respimat). Higher deposition 
rate (39% vs 11% Respimat vs MDI) of the drug 
in lungs is achieved when administered with 
a Respimat inhaler which makes it possible to use 
a smaller dose. The TIOSPIR (Tiotropium Safety 
and Performance in Respimat) study conducted 
with 17,135 COPD patients showed that the safety 
profile and efficacy of two available formulations 
of tiotropium are comparable [17]. The risk of 
death from any causes, the risk of cardiovascular 
death, the risk of severe cardiovascular incidents 
and adverse reactions as well as the risk of COPD 
exacerbations, including those requiring hospi-
talisation, were similar. The efficacy and safety of 
tiotropium have been evaluated in many clinical 
trials against placebo and several different active 
comparators (Table 2, Fig. 1).
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Table 2.  Summary of results of analyses comparing the effect of tiotropium vs a comparator on COPD exacerbations
Tabela 2.  Podsumowanie badań analizujacych wpływ tiotropium w porównaniu z innymi lekami badanymi na zaostrzenia 
POChP
Analysis Study
(treatment duration/
endpointa)
N
(n in the tio-
tropium group)
Incidence of 
exacerbations 
(reduction  
in risk)
Time to first  
exacerbation 
(reduction  
in risk)
Other exacerbation indexes
Tiotropium 
vs placebo
UPLIFT
(48 months/Y) [18]
5993 (2987) HR 0.86 (95% CI: 
0.81 to 0.91)
HR 0.86 (95% CI: 
0.81 to 0.91)
Hospitalised exacerbations HR 0.94 
(0.82 to 1.07)
time to first exacerbation — HR 0.86 
(95% CI: 0.78 to 0.95)
duration of exacerbations – HR 0.89 
(0.83 to 0.95)
duration of hospitalisation due to 
exacerbations — HR 1.01 (0.87 to 
1.18)
UPLIFT — subgroupb
(48 months/Y) [19] 
2739 (1384) HR 0.80 (95% CI: 
0.72 to 0.88)
HR 0.82 (95% CI: 
0.75 to 0.90)
Hospitalised exacerbations — HR 
0.80 (95% CI: 0.63 to 1.03)
time to first hospitalised exacerba-
tion — HR 0.74 (95% CI: 0.62 to 
0.88)
UPLIFT — subgroupb
(48 months/Y) [20] 
810 (403) HR 0.90 (95% CI: 
0.75 to 1.08)
nd nd
Meta-analysis of 9 stu-
dies (24 to 48 weeks/Y) 
[21] 
6171 (3309) HR 0.79 (95% CI: 
0.73 to 0.86)
nd hospitalised exacerbations — HR 
0.79 (95% CI: 0.65 to 0.96)
Meta-analysis of 22 
studies†
3 to 48 months/Y) [22] 
23,309 
(12,697)
OR 0.78 (95% CI: 
0.70 to 0.87)
nd hospitalisation caused by exacerba-
tions – RR 0.85 (95% CI: 0.71−1.00)
Tiotropium 
vs salme-
terol
POET-COPT
(12 months/Y) [23] 
7376 (3707) RR 0.89 (95% CI: 
0.83 to 0.96)
HR 0.83 (95% CI: 
0.77 to 0.90)
Time to first severe exacerbation — 
HR 0.72 (95% CI: 0.61 to 0.85)
moderate exacerbation — RR 0.93 
(95% CI: 0.86 to 1.00)
severe exacerbation — RR 0.73 
(95% CI: 0.66 to 0.82)
exacerbation treated with glucocorti-
costeroids administered systemically 
— RR 0.82 (95% CI: 0.76 to 0.90)
exacerbations treated with anti-
biotics
– RR 0.90 (95% CI: 0.84 to 0.97)
exacerbation treated with glucocorti-
costeroids administered systemically 
and antibiotics – RR 0.80 (95% CI: 
0.73 to 0.88)
Tiotropium 
vs ipratrio-
pium
review of 2 studies (12 
weeks and 12 months/N) 
[24] 
1073 (716) OR 0.71 (95% CI: 
0.52 to 0.95)
nd hospitalised exacerbations – OR 0.56 
(95% CI: 0.31 to 0.99) one study data
Tiotropium 
vs glycopy-
rronium 
GLOW5
III phase clinical trial [26] 
(12 weeks/Y)
657 (330) RR 1.10 (95% CI: 
0.62 to 1.93)
HR 1.33 
(95% CI: 0.76 to 
2.33)
hospitalised exacerbations – OR 0.79 
(95% CI: 0.21 to 2.94)
exacerbation treated with glucocorti-
costeroids administered systemically 
– OR 1.06 (95% CI: 0.55 to 2.04)
exacerbations treated with antibiotics 
– OR 1.48 (95% CI: 0.77 to 2.85) 
Tiotropium 
vs indaca-
terol
pooled analysis of 2 
studies
(12 and 26 weeks/N) [27] 
2856 (1221) HR 0.92 (95% CI: 
0.66 to 1.38)
nd nd
HR — hazard ratio, CI — confidence interval, OR — odds ratio; RR — relative risk, nd — no data 
aY/N — Evaluation of exacerbations as a study endpoint YES/NO 
bpatients with moderate COPD (stage II according to GOLD) 
ca subgroup of patients so far untreated/in whom tiotropium was used as the first maintenance therapy
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apatients with COPD at stage II according to GOLD 
bpatients so far untreated/in whom tiotropium was used as the first maintenance therapy
 
Figure 1. The effect of tiotropium vs comparator on the incidence of COPD exacerbations – the effect expressed as: hazard ratio (HR; A); relative 
risk (RR; B) or odds ratio (OR; C). Own compilation based on [18–24, 26, 27]
Rycina 1. Wpływ tiotropium w porównaniu z innymi lekami badanymi na czestość występowania zaostrzeń POChP przedstawiony jako współczynnik 
ryzyka (HR; A), ryzyko względne (RR; B) i iloraz szans (OR; C). Opracowanie własne na podstawie [18−24, 26, 27]
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Tiotropium vs placebo
The double-blind, randomised study UPLIFT 
(Understanding Potential Long-term Impacts on 
Function with Tiotropium) evaluated the benefits 
of using tiotropium for 4 years at the dose of 18 
μg compared to placebo [18]. There were 5993 
patients taking part in the study (including 2987 
in the tiotropium group) aged at least 40 years, 
with moderate to severe COPD, with a history of 
smoking of at least 10 pack-years. The patients 
could receive COPD drugs according to GOLD 
guidelines except for other anticholinergic inha-
lation drugs. Evaluation of progression of lung 
function impairment was the primary endpoint. 
Other evaluated parameters included quality of 
life, exacerbations of the disease, hospitalisations 
and mortality. The study showed that, compared 
to placebo, tiotropium decreased lung function 
decline in patients not using inhaled corticos-
teroids or other long-acting bronchodilators, it 
significantly improved the mean value of FEV1 
and the quality of life (as evaluated with SGRQ). 
Treatment with tiotropium extended the time be-
fore the first exacerbation (median 16.7 months) 
compared to the patients who received placebo 
(median 12.5 months). The incidence of exacer-
bation was found to be lower in the tiotropium 
group than in the placebo group by 14% (0.73 
vs 0.85 exacerbations/patient-year; hazard ratio 
(HR) 0.86) and the duration of exacerbations was 
shorter (12.1 vs 13.6 days/patient-year, HR 0.89). 
Moreover, treatment with tiotropium resulted 
in extending the time before an exacerbation 
leading to hospitalization (HR = 0.86). A still 
greater benefit for the endpoint regarding the 
effect on exacerbations has been shown by an 
analysis of the findings of the UPLIFT study in 
the subgroup of patients with moderate COPD 
(stage II according to the then valid GOLD stand-
ards). The number of exacerbations expressed in 
patient-years in the tiotropium group was lower 
by 20% than in the placebo group (HR 0.80; 
p < 0.0001). The time before an exacerbation or 
an exacerbation resulting in hospital admission 
was significantly longer in the tiotropium group 
than in the placebo group (HR 0.82 and 0.74; 
p < 0.0001 and p =0.001, respectively) [19]. The 
findings of another analysis of the UPLIFT study 
conducted in the subgroup of patients with COPD 
who have not been treated earlier indicate that the 
slow-down of annual decrease in FEV1 applies es-
pecially to patients in whom tiotropium was used 
as the first drug [20]. At least one exacerbation 
episode occurred in 55.6% of the patients in this 
subgroup treated with tiotropium and in 56.5% of 
patients who received placebo. There was a trend 
to lower incidence of exacerbations 16% in the 
tiotropium group compared to placebo, but the 
difference was not statistically significant (0.49 
vs 0.58 exacerbations/year; p = 0.08). The time 
before the first exacerbation was not statistically 
different in the groups (26.9 in the tiotropium 
group vs 20.6 months in the placebo group, p = 
0.24). Only 17% of patients suffered from an ex-
acerbation that required hospitalisation, and the 
difference between the incidence of this type of 
exacerbations in both groups was not statistically 
significant.
The efficacy of tiotropium in the prevention 
of COPD exacerbations was evaluated in a me-
ta-analysis of 9 randomised, placebo-controlled 
studies, with at least a 24-week follow-up period, 
covering a total of 6171 patients with COPD, in-
cluding 2862 in the tiotropium group (18 μg) [21]. 
The findings of the analysis have confirmed 
the observations made in the UPLIFT study. 
A 21% reduction in the risk of exacerbations 
was achieved in the tiotropium group (HR 0.79; 
p < 0.0001). The risk of exacerbations was found 
to be smaller in 8 out of 9 studies (the effect size 
from 14% to 48%) and it was found to be the 
same in one — HR 1.03. Similarly, the risk of 
exacerbations that required hospitalisations was 
lower by 21% in the tiotropium group compared 
to the placebo group (HR 0.79; p = 0.015). In this 
case, the hazard ratio was smaller than 1 in 6 out 
of 9 studies. The treatment with tiotropium also 
resulted in extending the time until the first exac-
erbation. An exacerbation occurred up to week 46 
in a much smaller percentage of patients treated 
with tiotropium (42.1% vs 50.8%). The treatment 
with tiotropium had a similar effect on the time 
until the first hospitalised exacerbation. A lower 
percentage of patients with hospitalised exacer-
bations was recorded in week 46 of the study in 
the tiotropium group compared to the control 
group (8.5% vs 10.8%). An additional analysis 
in subgroups confirmed that the beneficial effect 
of tiotropium on exacerbations did not depend 
on the age, gender, FEV1 or the use of inhaled 
glucocorticosteroids. 
An assessment of the efficacy of tiotropium 
was also the subject of a meta-analysis in the 
Cochrane library published in 2014, which as-
sessed the results of 22 randomised, placebo-con-
trolled clinical trials involving 23,309 COPD 
patients [22]. The follow-up period was between 
3 months and 4 years. Nineteen out of 22 studies 
evaluated efficacy of tiotropium administered 
with a Handihaler inhaler; in the other 3 — tiotro-
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pium was administered with a Respimat inhaler. 
An analysis of data from 22 studies showed that 
treatment with tiotropium significantly reduced 
the percentage of patients with exacerbations 
(38% vs 44%, odds ratio (OR) 0.78, 95% CI 0.70 
to 0.87). This means that in order to avoid one 
exacerbation episode, 16 patients should be treat-
ed with tiotropium for one year (number needed 
to treat, NNT = 16; 95% CI, 10 to 36). The risk 
of exacerbations was not found to depend on the 
type of inhaler used to administer tiotropium, 
severity of the disease, duration of treatment or 
the use of inhaled glucocorticosteroids. Addition-
ally, the effect of tiotropium on the incidence of 
hospitalised exacerbations was evaluated on the 
basis of 21 clinical trials. The percentage of pa-
tients who needed to be hospitalised because of 
exacerbations was lower in the tiotropium group 
than in the control group (10.4% vs 13.1%; OR 
0.85, 95% CI 0.72 to 1.00). 
Tiotropium vs Salmeterol 
The GOLD guidelines regarding COPD treat-
ment recommend the use of long-acting broncho-
dilators in order to alleviate the symptoms and 
reduce the risk of exacerbations in COPD patients 
at the moderate to severe stage, but it does not 
indicate whether long acting b2-agonists (LABA) 
or long-acting cholinolitics (LAMA) are preferred 
[8]. A one-year randomised, double-blind PO-
ET-COPD (Prevention Of Exacerbations with Ti-
otropium in COPD) study compared the efficacy of 
tiotropium (LAMA) at the dose of 18 μg once daily 
with salmeterol (LABA) at 50 μg twice daily in 
a group of 7,376 patients with moderate to severe 
COPD (stage II-IV according to GOLD) [23]. It was 
shown in regards to the main endpoint that tiotro-
pium treatment resulted in a longer (by 42 days) 
period until the first exacerbation than salmeterol 
(187 vs 145 days; time is defined as the number 
of days of treatment after which an exacerbation 
occurred; HR 0.83; p < 0.001). Compared to sal-
meterol treatment, the incidence of moderate and 
severe exacerbations in the group treated with ti-
otropium was smaller by 11% (0.64 vs 0.72 events/
patient-year; relative risk (RR) 0.89; p = 0.002) 
and the incidence of severe exacerbations was 
smaller by 27% (0.09 vs 0.13 events/patient-year; 
RR 0.73, p < 0.001). Moreover, the incidence 
of exacerbations which require treatment with 
glucocorticosteroids administered systemical-
ly, the incidence of exacerbations treated with 
antibiotics and the incidence of exacerbations 
which require treatment with antibiotics and 
glucocorticosteroids administered systemically 
was lower in the tiotropium group compared to 
the salmeterol group, by 18% (0.33 vs 0.41 RR 
0.82 and p < 0.001), 10% (0.53 vs 0.59 RR 0.90 
and p = 0.004) and 20% (0.23 vs 0.28 RR 0.80 and 
p < 0.001), respectively. An analysis in subgroups 
showed that the beneficial effect of tiotropium on 
the period until the first exacerbation and on the 
incidence of exacerbations (number of events per 
patient-year) did not depend on the age, gender, 
severity of the disease, smoking, BMI (body-mass 
index) or the use of inhaled glucocorticosteroids. 
Tiotropium vs ipratropium bromide
A comparison of efficacy of tiotropium with 
a short acting muscarinic antagonist (SAMA), ip-
ratropium bromide, was the subject of a systemat-
ic review from the Cochrane library published in 
2013 [24]. The analysis covered two randomised 
clinical trials with the follow-up period of at least 
12 weeks, in which a total of 1,073 patients with 
stable chronic obstructive pulmonary disease 
took part. Tiotropium was administered from 
a HandiHaler inhaler in one study (at 18 μg), and 
from a Respimat inhaler (at 5 and 10 μg) in the 
other. The following were observed in the study as 
compared to ipratropium treatment: improvement 
in pulmonary function (FEV1), better quality of 
life and a similar risk of death from any cause. In 
terms of exacerbations, both studies reported the 
number of patients with exacerbations, although 
an exacerbation episode was not defined clearly. 
A much smaller number of patients with at least one 
exacerbation was found in the tiotropium group 
compared to the ipratropium (OR 0.71). In one 
study, in which the incidence of exacerbations 
was also taken into account, it was shown that 
tiotropium treatment resulted in a 24% reduc-
tion in the incidence of exacerbations compared 
to ipratropium (0.73 vs 0.96; p = 0.006) [25]. 
Moreover, compared to ipratropium, tiotropium 
treatment considerably delayed the onset of an 
exacerbation, it extended the time until the first 
hospitalisation due to an exacerbation and short-
ened the period of exacerbations by 39% (10.8 
vs 17.7 days/patient-year, p = 0.002). There was 
a trend to lower incidence of hospitalisations 
caused by exacerbations by 38% in the tiotropium 
group compared to the ipratropium group, but the 
difference was not statistically significant (0.10 
vs 0.16; p = 0.08). 
Tiotropium vs glycopyrronium
Apart from tiotropium, there is also another 
LAMA taken once daily – glycopyrronium. In 
a randomised, blinded phase II clinical trial called 
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GLOW5 (Glycopyrronium bromide in COPD 
airWays clinical trial study), the effect of glyco-
pyrronium was compared to that of tiotropium in 
a group of 657 patients with moderate to severe 
COPD [26]. Glycopyrronium was administered at 
the dose 50 μg once daily, and tiotropium — at 
18 μg, also once daily. The treatment period was 
12 weeks. One of the secondary outcomes was 
an evaluation of the effect of glycopyrronium 
vs tiotropium on exacerbations. The number of 
patients with a moderate or severe exacerbation 
was low in both groups (9.7% and 7.5% in the 
glycopyrronium and tiotropium groups, respec-
tively). Similarly, the incidence of exacerbations 
in the groups of glycopyrronium and tiotropium 
was low and comparable (0.38 exacerbations 
a year vs 0.35 exacerbations a year; RR 1.10; p = 
0.754). The time until the first moderate or severe 
exacerbation of COPD did not differ significantly 
between the groups (HR 1.33; p = 0.324). No 
significant differences were observed between 
the glycopyrronium and the tiotropium groups 
in regards to the percentage of patients with ex-
acerbations leading to hospitalizations (0.7% vs 
1.0%, OR 0.79; p = 0.728), with exacerbations 
that require treatment with glucocorticosteroids 
administered systemically (6.0% vs 6.2%, OR 
1.06; p = 0.728) and with exacerbations that 
require antibiotic treatment (8.3% vs 5.8%; OR 
1.48; p = 0.236).
Tiotropium vs indacaterol
The effect of tiotropium and an ultra-long-act-
ing b2-agonist (ultraLABA), indacaterol, was com-
pared in one analysis in subgroups conducted as 
part of the systematic review from the Cochrane 
library in 2013 [27]. An analysis in the indaca-
terol subgroup covered randomised clinical trials 
with the follow-up period of at least 12 weeks, 
with the total of 2,856 patients with moderate or 
severe COPD [28, 29]. It must be mentioned that 
the tiotropium arm was not blinded in one of 
the studies [28]. Another issue is that the design 
of the analysed studies is different, number of 
patients varies between arms, and the definition 
of exacerbations may be slightly different in pre-
sented trials. No other exacerbation indexes were 
reported in either of the studies. 
Summary
Results of the clinical trials have confirmed 
a beneficial effect of tiotropium on exacerba-
tions. Compared to placebo, tiotropium reduces 
the incidence of exacerbation episodes, reduces 
the duration of exacerbations and delays onset 
of events, which also includes exacerbations 
leading to hospitalizations. The beneficial effect 
of tiotropium on exacerbations is particularly 
clear in patients with moderate COPD (stage II 
according to GOLD). Tiotropium is more effecti-
ve than salmeterol and ipratropium in terms of 
reduction in exacerbation incidence. The effect 
of tiotropium on exacerbations cannot be com-
pared to that of glycopyrronium and indacaterol 
because of limited clinical data and absence of 
statistically significant differences between the 
treatment regimens under study.
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